Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1705-1710

  Fidler, Mary Jo ^a   Basu, Sanjib ^a   Buckingham, Lela ^a   Walters, Kelly ^a   Mccormack, Sharon ^a   Batus, Marta ^a   Coon IV, John ^a   Bonomi, Philip ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EGFR; Gefitinib; IGF1R; Lung cancer; NSCLC

Indexed keywords

GEFITINIB; SOMATOMEDIN C RECEPTOR;

AGED; ARTICLE; CANCER PATIENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; IMMUNOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84861516194     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158, 2003. (Pubitemid 37432975)
2. Perez-Soler R: Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 6(Suppl 1): S20-23, 2004.
3. Shepherd FA, Rodrigues JP, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, and Seymour L for the National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
4. Thatcher N, Chang A, Parikh P, Rodritues JP, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Haiyi Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
6. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M and Kris MG: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29: 2066-2070, 2011.
7. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002. (Pubitemid 34074005)
8. Knowlden JM, Jones HE, Barrow D, Gee, JMW, Nicholson R and Hutcheson IR: Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: Implication for gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 111: 79-91, 2008. (Pubitemid 352009232)
9. Morgillo F, Woo JK, Kim ES, Hong WK and Lee HY: Heterodimerization of insulin-like growth factor receptor/ epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100-10111, 2006. (Pubitemid 44672064)
10. Hurbin A, Wislez M, Busser B, Antione M, Tenaud C, Rabbe N, Dufort S, deFraipont F, Moro-Sibilot D Cadranel J, Coll JL and Brambilla E: Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. J Pathol 225: 83-95, 2011.
11. Baserga R: The insulin receptor substrate-1: A biomarker for cancer? Exp Cell Res 315(5): 727-732, 2009.
12. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
13. Bellil Y, Burke AM, Chan IS, W. Mostertz and A. Potti; Department of Medicine, Duke University Medical Center, Durham, NC; University of North Carolina School of Medicine, Chapel Hill, NC; Duke Institute for Genome Sciences and Policy, Durham, NC; Duke University Medical Center, Durham, NC Clinical relevance of insulin regulatory pathways in nonsmall cell lung cancer progression. J Clin Oncol 28: 15(S) 7012, 2010.
14. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL and Engelman JA: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-2619, 2008. (Pubitemid 351949788)
15. Fidler MJ, Gimelfarb A, Dehghan-Paz I, Basu S, Fhied C, Kaiser K, Farlow E, Rouhi O, Batus M, Coon J, Bonomi P and Borgia JA. Insulin-like binding proteins and response in advanced NSCLC patients treated with erlotinib. World Conference on Lung Cancer Proceedings PD 7.3.5 2009.
16. Ludovini V, Bellezza G, Pistola L, Bianconi F, DiCarlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Marneli MG, Daddi G, Cavaliere A, Tonato M and Crino L. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal. growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20: 842-849, 2009.
17. Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, Mauer AM, Muzzafar T, Polowy C, Basu S, Gale M, Villaflor VM and Bonomi P: The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol 2: 414-422, 2007. (Pubitemid 47181696)
18. Velcheti V and Govindan R: Insulin-like growth factor and lung cancer. J Thorac Oncol 1: 607-610, 2006. (Pubitemid 47163945)
19. Han JY, Choi BG, Choi JY, Lee SY and Ju SY: The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 54: 227-234, 2006. (Pubitemid 44764920)
20. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P and Kurie JM: Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 62: 3530-3537, 2002. (Pubitemid 34651404)
21. Jones HE, Goddard L, Gee JM, Hiscox, S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE and Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793-814, 2004. (Pubitemid 40065552)
22. Zha J and Lackner MR: Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16: 2512-2517, 2010.
23. Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM and Shange Ys: Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: Immunohistochemical analysis. Korean J Intern Med 23: 116-120, 2008.
24. Dziadziuszko R, Merrick DT, Witta AD, Mendoza B and Szostakiewicz B: Insulin-like growth factor receptor 1 protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer. J Clin Oncol 27: 7524, 2009.
25. Wynes MW, Singh S, Dziadziuszko R, Jaskewicz K and Jassem J: Analysis of IGF1R gene copy number by silver in situ hybridization in non-small cell lung cancer. J Clin Oncol 27(15S): 7525, 2009.
26. Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A and Ryzyman W: High insulin-like growth factor 1 receptor expression is associated with poor survival in surgically treated non-small cell lung cancer patients. J Clin Oncol 25: 7550, 2007.
27. Cappuzzo F, Tallini G, Finocchiaro G, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelshmitt G, Klughammer B and Giaccone G: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 21(3): 562-7, 2010.
28. Kim J, Kim ES, Liu D, Lee J, Solis L, Yuan P, Behrens C, Hong WK, Wistuba II and Lee H: Comprehensive analysis of expression patters of insulin-like growth factor and SRC pathway in patients with non-small cell lung cancer; two large, independent series of tissue microarray. J Clin Oncol 28(15S): 10531, 2010.
29. Costa C, Gimenez Capitan A, Mayo C, Simonetti S, Majem M, Isla D, Benlloch S, Taron M, Sanchez A and Rosell R: Expression of MET, IGF1R, IL-6/GP130, and AXL in erlotinibtreated non-small cell lung cancer patients with EGFR mutations. J Clin Oncol 28(155): 7555, 2010.
30. Cappuzzo F, Toschi L, Tallini G, Seresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA, Santora A, Franklin WA, Varella-Garcia M and Hirsh FR: Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 17: 1120-1127, 2006. (Pubitemid 43985248)
31. Gualberto A, Hixon ML, Karp DD, Lee D, Green S, Dollid-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ and Pollack MN: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68-74, 2011.
32. Jassem J, Langer C, Karp DD, Mok T, Benner A, Green SJ, Park K, Novello S, Strausz J and Gualberto A: Randomized, open label, phase III trial of figitumumab in combiniation with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer. J Clin Oncol 28: 7500, 2010.
33. Habben K, Delmar, P, Brownstein CM, Koehler W, Kuenkele K, Spiesis O, Ramalingam SS, Engelman JA and Chen D: Investigations of predictive biomarkers for R1507, an anti-IGF1R antibody in patients advanced non-small-cell lung cancer with progression after first-line chemotherapy. J Clin Oncol 29: abstr. 7584, 2011.